| References |
1. Liu D, Ma X, Liu Y, Zhou H, Shi C, Wu F, Jiang J, Hu P. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. Eur J Pharm Sci. 2016 Jun 30;89:73-82. doi: 10.1016/j.ejps.2016.04.020. Epub 2016 Apr 21. PubMed PMID: 27108678. 2. Liu Y, Liu D, Liu H, Song H, Song L, Yao X, Wu F, Shu C, Ma X, Zhou H, Jiang J, Hu P. Simultaneous determination of imigliptin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:300-12. doi: 10.1016/j.jchromb.2015.08.003. PubMed PMID: 26355270. 3. Shu C, Ge H, Song M, Chen JH, Zhou H, Qi Q, Wang F, Ma X, Yang X, Zhang G, Ding Y, Zhou D, Peng P, Shih CK, Xu J, Wu F. Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2014 Jun 16;5(8):921-6. doi: 10.1021/ml5001905. PubMed PMID: 25147615; PubMed Central PMCID: PMC4137375. |
